个人简历

钱海，博士，研究员，博士生导师。2001年毕业于山东大学药学院药学专业，2007 获中国药科大学药物化学专业博士学位。现任职药物科学研究院新药研究中心，2010年评为副教授，2012年破格聘为博士生导师，2015年破格评为研究员。主要从事降血糖、抗肿瘤、逆转肿瘤多药耐药等方向的小分子及多肽药物的设计合成、生物活性及构效关系研究。2010年获第13届中国药学会-施维雅青年药物化学奖。江苏省“333高层次人才培养工程”第三层次培养对象。近5年发表SCI论文70余篇。参与申请中国专利 29项，国际专利2项，已授权13项。

研究领域

""新药分子设计与合成研究""""

近期论文

Zheng Li, XueXu, Wenlong Huang*, Hai Qian*. Free Fatty Acid Receptor 1 (FFAR1) As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Medicinal Research Reviews, 2017, DOI:10.1002/med.21441. (IF=8.79 )\r
\r
Qianqian Qiu, Baomin Liu, Jian Cui, Zheng Li, Xin Deng, HaoQiang, Jieming Li, Chen Liao, Bo Zhang, Wei Shi, Miaobo Pan, Wenlong Huang* and Hai Qian*, Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6, 7-Dimethoxy-3, 4-dihydroisoquinolin-2 (1-H)-yl)-ethyl)-phenyl)-quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(8): 3289-3302. (IF=6.259 )\r
\r
Qianqian Qiu, Wei Shi, Zheng Li, Bo Zhang, Miaobo Pan, Jian Cui, Yuxuan Dai, Wenlong Huang* and Hai Qian*, Exploration of 2-((Pyridin-4-ylmethyl) amino) nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(7): 2930-2943. (IF=6.259)\r
\r
Xue Li, Mian Fu, Jun Wu*, Chenyu Zhang, Xin Deng, ArvindDhinakar, Wenlong Huang, HaiQian*, Liang Ge*, pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. Acta Biomaterialia, 2017, 51: 294-303. (IF=6.319)\r
\r
Zheng Li, Qianqian Qiu, Xue Xu, Xuekun Wang, Lei Jiao, Xin Su, Miaobo Pan, Wenlong Huang*, Hai Qian*, Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes, European Journal of Medicinal Chemistry, 2016 , 113(20), 246-257. (IF=4.519)\r
\r
Xin Deng, Qianqian Qiu, Baowei Yang, Xuekun Wang, Wenlong Huang*, Hai Qian*. Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. European Journal of Medicinal Chemistry, 2015, 89(1), 540-548. (IF=4.519)\r
\r
Jing Han, Lidan Sun, Xun Huang, Zheng Li, Chenyu Zhang, Hai Qian* and Wenlong Huang*. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. British Journal of Pharmacology，2014，171 (23) 5252–5264. (IF=5.49)\r
\r
Baowei Yang, Yicheng Mei, Xuekun Wang, Xin Deng, Hai Qian*, Wenlong Huang*. Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents. European Journal of Medicinal Chemistry, 2014, (73),105-111. (IF=4.519)\r
\r
Jing Han, Lidan Sun, Yingying Chu, Zheng Li, Dandan Huang, Xiaoyun Zhu, Hai Qian*, Wenlong Huang*. Design, Synthesis and Biological activity studies of Novel Dicoumarin-Glucagon-Like Peptide-1 Conjugates. Journal of Medicinal Chemistry, 2013，56(24), 9955-9968. (IF=6.259)\r
\r
Jing Han, Xun Huang, Lidan Sun, Zheng Li, Hai Qian*, Wenlong Huang*, Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochemical Pharmacology, 2013, 86(2), 297-308. (IF=4.58)